MARKET

PDSB

PDSB

PDS Biotechnology Corporation
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.705
+0.035
+2.10%
Opening 13:37 07/06 EDT
OPEN
1.640
PREV CLOSE
1.670
HIGH
1.730
LOW
1.628
VOLUME
354.82K
TURNOVER
--
52 WEEK HIGH
6.71
52 WEEK LOW
0.6153
MARKET CAP
26.19M
P/E (TTM)
-0.5638
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PDSB stock price target is 6.48 with a high estimate of 10.00 and a low estimate of 4.000.

EPS

PDSB News

More
GNW, WKHS, ZYNE and BE among midday movers
Seeking Alpha - Article · 6d ago
GNW, IIPR among premarket losers
Seeking Alpha - Article · 6d ago
ICPT, WKHS, HRTX and BLNK among midday movers
Seeking Alpha - Article · 06/29 16:41
NKLA, COTY among premarket gainers
Seeking Alpha - Article · 06/29 12:24
GPS, LK, IBIO and MMLP among midday movers
Seeking Alpha - Article · 06/26 16:42
PDS Biotechnology Shares Move Higher; Hearing Co. To Present Key Data For Developing SARS-CoV-2 Program Based On Versamune Platform
-Chardan
Chardan · 06/26 16:20
PDS Biotech Announces Publication of Preclinical Results Of PDS0101 Combination By The National Cancer Institute In The Journal For ImmunoTherapy Of Cancer
PDS Biotech Announces Publication of Preclinical Results of PDS0101 Combination by the National Cancer Institute in the Journal for ImmunoTherapy of Cancer FLORHAM PARK, N.J., June 22, 2020 (GLOBE NEWSWIRE) -- PDS
Benzinga · 06/22 12:34
PDS Biotech Announces Publication of Preclinical Results of PDS0101 Combination by the National Cancer Institute in the Journal for ImmunoTherapy of Cancer
PDS Biotechnology Corporation (PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced the publication of data g
GlobeNewswire · 06/22 12:30

Industry

Biotechnology & Medical Research
+1.01%
Pharmaceuticals & Medical Research
+0.95%

Hot Stocks

Symbol
Price
%Change

About PDSB

PDS Biotechnology Corp, formerly Edge Therapeutics, Inc., is an immuno-oncology company, The Company is focused on developing a pipeline of clinical-stage immunotherapies. Its therapies are developed for the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Versamune is its synthetic lipid-based immunotherapy platform. Its lead product candidate, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. Its pipeline also includes PDS0102, PDS0103 and PDS0104. Its pipeline of Versamune-based products are all administered by subcutaneous injection .DS0102 is being developed for the treatment of prostate and breast cancers. PDS0103 is based on novel agonist antigens of the mucin-1 (MUC-1) oncogenic C-terminal region. PDS0104 is being developed for the treatment of melanoma.
More

Webull offers kinds of PDS Biotechnology Corp stock information, including NASDAQ:PDSB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PDSB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PDSB stock methods without spending real money on the virtual paper trading platform.